Industry Opposes Mandatory Prescriber Training for Opioids

Drugmakers’ biggest concern about the impact of a classwide risk evaluation and mitigation strategy (REMS) for long-acting and extended-release opioid pain drugs was that a requirement for mandatory physician training might cause physicians to stop prescribing the medications. Industry also expressed concerns that a compulsory training program would shift prescribing to short-acting opioids and combination products not covered by the FDA’s draft REMS, members of an industry working group told the FDA Friday.
Drug Industry Daily